# Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

> **NCT00816426** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 19 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Kanamycin
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT00816426
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-29
- **Primary completion:** 2014-08-26
- **Final completion:** 2017-12-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00816426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00816426, "Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00816426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*